↓ Skip to main content

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Overview of attention for article published in Journal of Clinical Oncology, October 2007
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Citations

dimensions_citation
570 Dimensions

Readers on

mendeley
217 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study
Published in
Journal of Clinical Oncology, October 2007
DOI 10.1200/jco.2007.11.3357
Pubmed ID
Authors

Charles S. Fuchs, John Marshall, Edith Mitchell, Rafal Wierzbicki, Vinod Ganju, Mark Jeffery, Joseph Schulz, Donald Richards, Raoudha Soufi-Mahjoubi, Benjamin Wang, José Barrueco

Abstract

This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI).

Mendeley readers

The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 4 2%
Japan 3 1%
Ecuador 2 <1%
United Kingdom 1 <1%
Hong Kong 1 <1%
Russia 1 <1%
Spain 1 <1%
France 1 <1%
United States 1 <1%
Other 0 0%
Unknown 202 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 55 25%
Other 46 21%
Student > Ph. D. Student 21 10%
Student > Bachelor 15 7%
Professor > Associate Professor 14 6%
Other 52 24%
Unknown 14 6%
Readers by discipline Count As %
Medicine and Dentistry 146 67%
Agricultural and Biological Sciences 20 9%
Biochemistry, Genetics and Molecular Biology 9 4%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Chemistry 3 1%
Other 15 7%
Unknown 17 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2017.
All research outputs
#417,037
of 12,172,179 outputs
Outputs from Journal of Clinical Oncology
#1,215
of 12,507 outputs
Outputs of similar age
#407,081
of 11,514,973 outputs
Outputs of similar age from Journal of Clinical Oncology
#1,199
of 12,007 outputs
Altmetric has tracked 12,172,179 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,507 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 11,514,973 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 12,007 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.